Portal de Periódicos da CAPES

Treatment of Depression with Botulinum Toxin A: A Case Series

2006; Lippincott Williams & Wilkins; Volume: 32; Issue: 5 Linguagem: Inglês

10.1111/j.1524-4725.2006.32136.x

1524-4725

Eric Finzi, Erika L. Wasserman,

Obsessive-Compulsive Spectrum Disorders

Dermatologic SurgeryVolume 32, Issue 5 p. 645-650 Treatment of Depression with Botulinum Toxin A: A Case Series ERIC FINZI MD, PhD, ERIC FINZI MD, PhD Dermatology & Cosmetic Surgery Associates, Greenbelt, Maryland Chevy Chase Cosmetic Center, Chevy Chase, MarylandSearch for more papers by this authorERIKA WASSERMAN PhD, ERIKA WASSERMAN PhD William Stixrude and Associates, Bethesda, MarylandSearch for more papers by this author ERIC FINZI MD, PhD, ERIC FINZI MD, PhD Dermatology & Cosmetic Surgery Associates, Greenbelt, Maryland Chevy Chase Cosmetic Center, Chevy Chase, MarylandSearch for more papers by this authorERIKA WASSERMAN PhD, ERIKA WASSERMAN PhD William Stixrude and Associates, Bethesda, MarylandSearch for more papers by this author First published: 12 May 2006 https://doi.org/10.1111/j.1524-4725.2006.32136.xCitations: 10 Address correspondence and reprint requests to: Eric Finzi, MD, PhD, 8401 Connecticut Ave., Suite 210, Chevy Chase, MD 20815, or email: efinzi@starpower.net Read the full textAboutPDF ToolsExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract BACKGROUND Major depression is a common and serious disease that may be resistant to routine pharmacologic and psychotherapeutic treatment approaches. OBJECTIVE To evaluate the efficacy of botulinum toxin A treatment of glabellar frown lines in treating patients with major depression, using a small open pilot trial. METHODS Patients who met DSM-IV criteria for ongoing major depression in spite of pharmacologic or psychotherapeutic treatment were evaluated with the Beck Depression Inventory II (BDI-II) before receiving botulinum toxin A to their glabellar frown lines. Two months later, all patients were re-evaluated clinically and with the BDI-II. RESULTS Ten depressed patients were treated with botulinum toxin A, and 9 of 10 patients were no longer depressed 2 months after treatment. The tenth patient had an improvement in mood. CONCLUSION To our knowledge, these are the first reported cases of depression treated with botulinum toxin A. Citing Literature Volume32, Issue5May 2006Pages 645-650 RelatedInformation